DNA and RNA Vaccines for Aquaculture

DNA vaccines introduce a small circular piece of DNA encoding a specific pathogen protein directly into fish muscle cells, which then produce that protein themselves, triggering an immune response against it without ever exposing the fish to any live or inactivated pathogen material, a fundamentally different vaccine mechanism from conventional inactivated or attenuated whole-pathogen vaccines, and one that has achieved notable commercial success specifically against certain viral fish diseases where conventional vaccine approaches had previously struggled to achieve adequate protective efficacy. RNA-based vaccine approaches, using messenger RNA to similarly direct fish cells to produce a target pathogen protein without any DNA integration step, represent a newer technology still earlier in aquaculture-specific commercial development relative to DNA vaccines, though the mRNA vaccine platform's dramatically accelerated maturation and manufacturing scale-up during recent human vaccine development has generated substantial secondary interest in adapting the same underlying technology and manufacturing infrastructure toward aquaculture applications. A key regulatory and public-perception distinction between DNA and RNA vaccine platforms, genetic modification concerns around DNA vaccines since the introduced genetic material is technically foreign DNA even though it does not alter the fish's own genome, versus RNA vaccines which some regulatory frameworks and consumer perception treat somewhat differently given mRNA's inherently transient, non-integrating nature, has shaped how different jurisdictions have approached approval and consumer-facing disclosure requirements for each respective vaccine technology. Manufacturing and cost advantages for both DNA and RNA vaccine platforms relative to some conventional vaccine production methods, generally faster development timelines once the target antigen sequence is known and more standardized production processes across different target diseases, have driven continued aquaculture-sector research investment in both technologies as a complement to, rather than necessarily full replacement for, established conventional inactivated and attenuated vaccine platforms that remain effective and commercially proven for many other fish diseases.